Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
1.
São Paulo; s.n; s.n; 2022. 116 p. tab, graf.
Thesis in English | LILACS | ID: biblio-1378343

ABSTRACT

Stem cells are undifferentiated cells that can be distinguished from others by their ability to self-renew and to differentiate into new specific cell types. Mesenchymal stem cells (MSC) are adult stem cells that can be obtained from different sources, such as adipose tissue, bone marrow, dental pulp, and umbilical cord. They can either replicate, originating new identical cells, or differentiate into cells of mesodermal origin and from other germ layers. MSC have been studied as new tools for regenerative therapy. Although encouraging results have been demonstrated, MSC-based therapies still face a great barrier: the difficulty of isolating these cells from heterogeneous environments. MSC are currently characterized by immunolabelling through a set of multiple surface membrane markers, including CD29, CD73, CD90 and CD105, which are also expressed by other cell types. Hence, the present work aimed to identify new specific biomarkers for the characterization of human MSC using DNA aptamers produced by the SELEX (Systematic Evolution of Ligands by EXponential Enrichment) technique. Our results showed that MSC from different origins bound to DNA candidate aptamers, that is, DNA or RNA oligonucleotides selected from random libraries that bind specifically to biological targets. Aptamer-bound MSC could be isolated by fluorescenceactivated cell sorting (FACS) procedures, enhancing the induction of differentiation into specific phenotypes (chondrocytes, osteocytes and adipocytes) when compared to the whole MSC population. Flow cytometry analyses revealed that candidate aptamers bound to 50% of the MSC population from dental pulp and did not present significant binding rates to human fibroblasts or lymphocytes, both used as negative control. Moreover, immunofluorescence images and confocal analyses revealed staining of MSC by aptamers localized in the surfacemembrane of these cells. The results also showed internal staining of human monocytes by our investigated aptamers. A non-specific control aptamer (CNTR APT) obtained from the random pool was then utilized to compare the specificity of the aptamers bound to the analyzed non-apoptotic cells, showing no staining for MSC. However, 40% of the monocytes bound to the CNTR APT. Normalized data based on the cells bound to candidate aptamers compared to those bound to the CNTR APT, revealed a 10 to 16-fold higher binding rate for MSC against 2-fold for monocytes. Despite its low specificity, monocyte-aptamer binding occurs probably due to the expression of shared markers with MSC, since monocytes are derived from hematopoietic stem cells and are important for the immune system ability to internalize/phagocyte external molecules. Given that, we performed a pull-down assay followed by mass spectrometry analysis to detect which MSC-specific protein or other target epitope not coexpressed by monocytes or the CNTR APT would bind to the candidate aptamer. Distinguishing between MSC and monocyte epitopes is important, as both cells are involved in immunomodulatory effects after MSC transplantations. ADAM17 was found to be a target of the APT10, emerging as a possible biomarker of MSC, since its involvement in the inhibition of the TGF signaling cascade, which is responsible for the differentiation of MSC. Thus, MSC with a higher stemness profile should overexpress the protein ADAM17, which presents a catalytic site with affinity to APT10. Another target of Apt 10 is VAMP3, belonging to a transmembrane protein complex that is involved in endocytosis and exocytosis processes during immune and inflammatory responses. Overall, proteins identified as targets of APT10 may be cell surface MSC biomarkers, with importance for MSC-based cell and immune therapies


Células tronco são células indiferenciadas que podem ser distinguidas de outros tipos celulares por meio da habilidade de se auto renovarem e de se diferenciarem em novos tipos celulares. Células tronco mesenquimais (MSC) são células tronco adultas encontradas em diferentes tecidos como tecido adiposo, polpa de dente e cordão umbilical. Estas células podem se autodividir em células idênticas ou se diferenciarem em células de origem mesodermal. Estas células têm sido estudadas em novas aplicações que envolvem terapia regenerativas. Embora resultados encorajadores tenham sido demonstrados, terapias que utilizam MSC ainda encontram uma grande barreira: a dificuldade no isolamento destas células a partir de um ambiente heterogêneo. MSC são caracterizadas por populações positivas em ensaios de imunomarcação para os epítopos membranares CD29, CD73, CD90 e CD105, presentes também em outros tipos celulares. Assim, o presente trabalho tem o objetivo de identificar novos biomarcadores de MSC de origem humana, utilizando aptâmeros de DNA produzidos pela técnica SELEX (Systematic Evolution of Ligands by EXponential Enrichment) como ferramenta. Nossos resultados mostraram que MSC de diferentes origens ligam-se a aptâmeros (oligonucleotídeos de DNA ou RNA que atuam como ligantes específicos de alvos moleculares) de DNA candidatos que atuam no isolamento de MSC por meio da técnica FACS de separação celular, promovendo uma maior indução de diferenciação em células específicas (condrócitos, osteócitos e adipócitos) comparada com a população total de MSC. Análises de citometria de fluxo mostraram que os aptâmeros candidatos se ligam a 50% das MSC de polpa de dente e não apresentam taxa de ligação significante para fibroblastos e linfócitos de origem humana - utilizados como controles negativo. Além domais, imagens de imunofluorescência e confocal mostraram ligação na superfície da membrana de MSC e a marcação interna de monócitos a estes aptâmeros. Portanto, um aptâmero controle (CNTR APT) foi utilizado para comparar a especificidade dos aptâmeros ligados a células viáveis, mostrando a não ligação deste aptâmero a MSC. Porém, 40% da população de monócitos ligou-se ao CNTR APT. Uma normalização baseada na comparação entre as taxas de ligação entre células ligadas com aptâmeros candidatos e o aptâmero controle gerou uma taxa de especificidade entre 10-16 vezes maior para MSC contra 2,5 vezes para os monócitos. Deste modo, embora os resultados tenham mostrado uma taxa de ligação entre monócitos e aptâmeros, as MSC ligadas aos aptâmeros candidatos possuem uma maior taxa de especificidade devido a uma maior presença de antígenos que são expressos em ambas as células. Um ensaio de Pull Down seguido de espectrometria de massas foi utilizado para a identificação de biomarcadores que se ligariam aos aptâmeros candidatos, e que não seriam co-expressos por monócitos e por antígenos ligados ao aptâmero controle. Deste modo, a proteína ADAM17 foi identificada nas amostras de APT10 ligadas às MSC. Tal proteína está relacionada à inibição de uma cascata de sinalização da família de proteínas TGF, responsável pela diferenciação de MSC. Assim, MSC com maior potencial tronco deveriam expressar ADAM17 em maior quantidade. Tal proteína apresenta um sítio catalítico que demonstra interagir com o APT10, de acordo com predição Docking entre proteína e DNA. Foi identificada também, a proteína VAMP3, que pertence a um complexo proteico transmembranar responsável pelos processos de endocitose e exocitose, e que podem ter um papel importante na liberação de citocinas e outras moléculas relacionadas às respostas imune e inflamatórias. Deste modo, o APT10 identificou proteínas importantes que devem estar relacionas com a melhora de imunoterapias que utilizam MSC


Subject(s)
Stem Cells , Biomarkers/analysis , SELEX Aptamer Technique/instrumentation , Mesenchymal Stem Cells/classification , ADAM17 Protein/pharmacology , Patient Isolation , Mass Spectrometry/methods , Staining and Labeling/methods , Transplantation/adverse effects , Umbilical Cord , DNA/agonists , Transforming Growth Factors/agonists , Cell Separation/instrumentation , Cytokines/adverse effects , Adipocytes/metabolism , Chondrocytes/classification , Scientists for Health and Research for Development , Adult Stem Cells/classification , Fibroblasts/chemistry , Flow Cytometry/instrumentation , Germ Layers , Antigens/adverse effects
2.
Arq. bras. endocrinol. metab ; 58(5): 484-492, 07/2014. tab, graf
Article in English | LILACS | ID: lil-719207

ABSTRACT

Organ transplantation is the gold standard therapy for several end-stage diseases. Bone loss is a common complication that occurs in transplant recipients. Osteoporosis and fragility fractures are serious complication, mainly in the first year post transplantation. Many factors contribute to the pathogenesis of bone disease following organ transplantation. This review address the mechanisms of bone loss including the contribution of the immunosuppressive agents as well as the specific features to bone loss after kidney, lung, liver, cardiac and bone marrow transplantation. Prevention and management of bone loss in the transplant recipient should be included in their post transplant follow-up in order to prevent fractures.


Transplantes de órgão é terapia padrão-ouro para várias doenças em estágio terminal. Perda óssea é uma complicação comum que ocorre em pacientes transplantados. Osteoporose e fraturas por fragilidade são complicações sérias, principalmente no primeiro ano pós-transplante. Muitos fatores podem contribuir para patogênese da doença óssea nesses pacientes. Esta revisão aborda os mecanismos de perda óssea incluindo o papel dos agentes imunossupressores, bem como os fatores específicos da perda óssea após rim, pulmão, fígado, coração e transplante de medula óssea. A prevenção e o tratamento da perda óssea nos pacientes transplantados devem ser realizados para evitar fraturas.


Subject(s)
Humans , Bone Diseases/etiology , Bone Diseases/prevention & control , Bone Resorption/etiology , Immunosuppressive Agents/adverse effects , Osteoporotic Fractures/etiology , Transplantation/adverse effects , Bone Marrow Transplantation/adverse effects , Calcium/blood , Diphosphonates/therapeutic use , Heart Transplantation/adverse effects , Kidney Transplantation/adverse effects , Liver Transplantation/adverse effects , Lung Transplantation/adverse effects , Vitamin D/therapeutic use
3.
Rev. med. (Säo Paulo) ; 91(4): 229-240, out.-dez. 2012. ilus, tab, graf
Article in Portuguese | LILACS | ID: lil-747307

ABSTRACT

Dentre as diversas etiologias da insuficiência cardíaca, a miocardiopatia chagásica é considerada a mais agressiva. Como não há tratamento capaz de reverter a evolução da doença o transplante cardíaco torna-se a únicaopção. Foram analisados 107 pacientes portadores da doença de Chagas submetidos a transplante cardíaco, com idades compreendidas entre 11 e 62 anos (42,7±15,3 anos). Os pacientesportadores de megaesôfago e megacólon sintomáticos são automaticamente excluídos dos programas de transplante devido a uma maior possibilidade de complicações no pós-operatório a curto e longo prazo. A expectativa de resultados inferiores para o transplante em chagásicos em relação às demais cardiomiopatias não foi confirmada e, paradoxalmente,se encontram melhores taxas de sobrevida. Notou-se uma mortalidade imediata de 17,7% (19 casos), sendo as principais causas de morte: infecção (6 casos, 31,5%), disfunção do enxerto (6 casos, 31,5%), rejeição (4 casos 21,1%), parada cardiorrespiratória súbita (2 casos 10,5%) e incompatibilidades ABO (1 caso 5,3%). Tardiamente ao transplante, 27 (25,2%) pacientes morreram, sendo as principais causas de morte: rejeição (6 casos, 22,2%), infecção (6 casos, 22,2%), linfoma (4 casos, 14,8%), Kaposi (2 casos, 7,4%), pericardite constritiva (2 casos, 7,4%) e reativação da doença de Chagas no sistemanervoso central (1 caso, 7,1%). Por fim, pode-se concluir que: 1) o transplante cardíaco ainda é a única forma capazde modificar a evolução natural da cardiomiopatia chagásica; 2) o diagnóstico precoce aliado à rápida introdução de benzonidazol leva a um reconhecimento de padrões histológicosnormais do miocárdio sem que haja sequelas e 3) as doses de imunossupressores empregadas devem ser inferiores às utilizadas em outras etiologias.


Among the several etiologies of heart failure, the chagasic myocardiopathy is considered the most aggressive. Once there is no treatment capable of reverting the disease evolution, the heart transplantation becomes the only option. We analyzed 107 patients with Chagas disease submitted to heart transplantation, aged between 11 and 62 years (42.7 ± 15.3 years). Patients with symptomatic megacolon andmegaesophagus are automatically excluded from transplant programs due to a higher possibility of postoperative short and long term complications. The expectation of inferior results for the transplantation of chagasic patients in comparison with other myocardiopathies was not confirmed and, paradoxically, were found better survival rates. We noticed an immediatemortality rated in 17.7% (19 cases), whose main cause of death were: infection (6 cases, 31.5%), graft dysfunction (6 cases, 31.5%), rejection (4 cases 21,1%), sudden cardiopulmonary arrest (2 cases 10.5%) and ABO incompatibilities (1 case 5,3%). Late after transplant, 27 (25.2%) patients died, and the majorcauses were: rejection (6 cases, 22.2%), infection (6 casos, 22.2%), lymphoma (4 cases, 14.8%), Kaposi sarcoma (2 cases, 7.4%), constrictive pericarditis (2 cases, 7.4%) and Chagas disease reactivation in the central nervous system (1 case, 7.1%). Finally, the conclusions are: 1) heart transplantation is still the only way to modify the natural course of chagasicmyocardiopathy, 2) early diagnosis coupled to the rapid introduction of benzonidazol leads to a pattern recognition of normal myocardial histology without sequelae and 3) the doses of immunosuppressants used should be lower than those usedin other etiologies.


Subject(s)
Humans , Child , Adolescent , Young Adult , Middle Aged , Chagas Cardiomyopathy/diagnosis , Chagas Cardiomyopathy/etiology , Cardiomyopathies , Chagas Disease/etiology , Immunosuppression Therapy , Graft Rejection/prevention & control , Heart Transplantation , Transplantation/adverse effects
4.
SJO-Saudi Journal of Ophthalmology. 2011; 25 (3): 301-303
in English | IMEMR | ID: emr-129886

ABSTRACT

This case report presents a case that had Descemef s stripping automated endothelial keratoplasty complicated postoperatively by detached donor grafts. The patient had a well centered partially detached graft that attached spontaneously the next day without the need to re-bubble. Postoperatively he had a clear cornea, improved uncorrected visual acuity with good endothelial cell count. It is worth waiting for a partially detached well centered graft to adhere spontaneously; this would lower the possible risks of repeated anterior chamber air injections. Cases should be selected to eliminate any mechanical factor that would prevent the attachment


Subject(s)
Humans , Male , Middle Aged , Cornea , Corneal Transplantation/methods , Transplantation/adverse effects , Persuasive Communication
5.
Rev. Fac. Med. (Caracas) ; 32(2): 166-170, dic. 2009. ilus, tab
Article in Spanish | LILACS | ID: lil-631568

ABSTRACT

El polimetil-metacrilato es un polímero de alta resistencia al impacto, ampliamente utilizado en diferentes campos de la medicina, sin embargo, aún no está clara su indicación como relleno glúteo. A pesar de su aparente inocuidad, se han presentado complicaciones durante su uso como granulomas y nódulos palpables. Se han reportado casos de embolismo pulmonar por polimetil-metacrilato posterior a vertebroplastias. Sin embargo, no se encontró reporte bibliográfico de casos de embolismo pulmonar con su uso en procedimientos estéticos. Presentamos caso de paciente femenino de 31 años de edad, quien 4 horas luego de la inyección de 500 cm3 de polimetil-metacrilato en cada región glútea, presenta disnea en reposo de aparición súbita con tos seca y palpitaciones, disminución de agudeza visual y petequias generalizadas. Se diagnostica probable embolismo pulmonar por polimetil-metacrilato y retinopatía de Purtscher. Existe similitud clínica e imaginología del caso en estudio con embolismo por silicone, y las imágenes del fondo de ojo semejan la obstrucción de pequeñas arteriolas retinianas compatibles con este diagnóstico. Se sugieren nuevas investigaciones en el uso de polimetil-metacrilato como procedimiento estético en pro de la seguridad y en beneficio de los pacientes


Polymethyl-methacrylate is a high impact resistant polymer, widely used in different medicine fields, however its indication in buttock implants is still not clear. Even though its apparent innocuity, it has presented complications like granulomas and palpable nodules. There have been reported cases of pulmonary embolism caused by polimetil-metacrilato secondary to vertebroplasties. However, there have been no bibliographic cases of pulmonary embolism due to its use in aesthetic procedures. We present a case of a woman patient of 31 years old, who 4 hours after 500 cc injection of polymethyl- Methacrylate in each buttock, presents rest dyspnea with abrupt dry cough and palpitations, reduction in visual acuity and generalized petechiae. It is diagnosed probable pulmonary embolism by polimetil-metacrilato and Purtscher retinopathy. There is a clinical and imaginological similitude between this case and silicone embolism and the images of fondoscopy are similar to those of small retinian arteriole obstruction compatible with the diagnosis. Thereby, it is suggested new investigations in the use of polymethyl-methacrylate as esthetic procedure in favor of the patient’s security and benefit


Subject(s)
Humans , Adult , Female , Dyspnea/pathology , Lung Diseases/pathology , Polymethyl Methacrylate/adverse effects , Silicones/adverse effects , Transplantation/adverse effects , Vertebroplasty/methods , Surgery, Plastic
8.
Clinics ; 62(1): 69-76, Feb. 2007. ilus, tab
Article in English | LILACS | ID: lil-441828

ABSTRACT

PURPOSE: To present the more frequent associations found in autopsies of immunocompromised patients who developed secondary interstitial pneumonia as well as the risk of death (odds ratio) in having specific secondary interstitial pneumonia according to the cause of immunocompromise. METHOD: From January 1994 to March 2004, 17,000 autopsies were performed at Hospital das Clínicas, São Paulo University Medical School. After examining the pathology report review, we selected 558 of these autopsies (3.28 percent) from patients aged 15 years or more with primary underlying diseases who developed radiologically diffuse infiltrates of the lung during their hospital course and died after secondary interstitial pneumonia (bronchopneumonia, lobar pneumonia, interstitial pneumonia, diffuse alveolar damage, pulmonary recurrence of underlying disease, drug-induced lung disease, cardiogenic pulmonary edema, or pulmonary embolism). Histology slides were reviewed by experienced pathologists to confirm or not the presence of secondary interstitial pneumonia. Statistical analysis included the Fisher exact test to verify any association between histopathology and the cause of immunocompromise; a logistic regression was used to predict the risk of death for specific histological findings for each of the independent variables in the model. RESULTS: Secondary interstitial pneumonia was histologically represented by diffuse interstitial pneumonitis ranging from mild nonspecific findings (n = 213) to a pattern of diffuse alveolar damage (n = 273). The principal causes of immunocompromise in patients with diffuse alveolar damage were sepsis (136 cases), neoplasia (113 cases), diabetes mellitus (37 cases), and transplantation (48 cases). A high risk of death by pulmonary edema was found for patients with carcinoma of colon. Similarly, in patients with lung cancer or cachexia, A high risk of death by bronchopneumonia (OR = 3.6; OR = 2.6, respectively) was found. Pulmonary...


OBJETIVO: Apresentar as associações mais freqüentes encontradas em autópsias de pacientes imunossuprimidos que desenvolveram pneumonia intersticial secundária bem como o risco de óbito (Odds Ratio) de desenvolver PIS associada à causa da imunossupressão. MÉTODO: De janeiro de 1994 a março de 2004, 17000 autópsias foram realizadas no Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. A partir da revisão dos laudos patológicos foram selecionados 558 destas autópsias (3,28 por cento) de pacientes com 15 anos de idade ou mais, com alguma doença de base que desenvolveu um infiltrado pulmonar radiologicamente difuso durante o curso da hospitalização e que depois foi para óbito com pneumonia intersticial secundária (broncopneumonia, pneumonia lobar, pneumonia intersticial, dano alveolar difuso, doença pulmonar recorrente, doença pulmonar induzida por drogas, edema pulmonar cardiogênico e embolismo pulmonar). As lâminas histológicas foram revisadas por patologistas experientes para confirmar ou não a presença de pneumonia intersticial secundária. A análise estatística incluiu o "Teste exato de Fisher" para verificar associação entre a histolopatologia e causa de imunocomprometimento; e regressão logística para predizer o risco de óbito por achados histológicos específicos para cada variável independente do modelo. RESULTADOS: A pneumonia intersticial secundária foi representada histológicamente por pneumonite intersticial difusa variando de características não especificas leves (n=213) ao padrão histológico de dano alveolar difuso (n=273). A principal causa de imunossupressão nos pacientes com dano alveolar difuso foi sepse (136 casos), neoplasia (113 casos), diabetes melito (37 casos) e transplantados (37 casos). O maior risco de morte por edema pulmonar foi encontrado nos pacientes com carcinoma de cólon. Da mesma forma, nos pacientes com câncer pulmonar ou cachexia ocorreu um alto risco de morte (OR=3.6; OR=2.6, respectivamente)...


Subject(s)
Humans , Male , Female , Cytomegalovirus , Cytomegalovirus Infections/mortality , Immunocompromised Host , Lung Diseases, Interstitial/mortality , Autopsy , Brazil , Cause of Death , Cytomegalovirus Infections/complications , Cytomegalovirus Infections/immunology , Cytomegalovirus/isolation & purification , Diabetes Complications , Hematologic Diseases/complications , Logistic Models , Lung Diseases, Interstitial/immunology , Lung Diseases, Interstitial/virology , Odds Ratio , Pulmonary Alveoli/pathology , Steroids/adverse effects , Transplantation/adverse effects
9.
Bahrain Medical Bulletin. 2007; 29 (2): 74-76
in English | IMEMR | ID: emr-81963

ABSTRACT

Aorto-enteric fistula is a serious and fatal complication of aortic graft surgery. The difficulty in both diagnosis and management amplify the impact and seriousness of this condition. Reports about the value of the use of endoscopy as a diagnostic tool are increasing in the medical field. Here we present our experience with a case of secondary aorto-duodenal fistula [ADF] followed by discussion of the current scientific opinion about this life threatening condition


Subject(s)
Humans , Male , Fistula , Aorta , Transplantation/adverse effects , Aortic Valve/surgery , Heart Valve Prosthesis , Endoscopy
10.
Arq. bras. endocrinol. metab ; 50(4): 783-792, ago. 2006. ilus
Article in English, Portuguese | LILACS | ID: lil-437628

ABSTRACT

In the past two decades, there has been a rapid increase in the number of organ transplanted worldwide, including Brazil, along with an improvement in survival and quality of life of the transplant recipients. Osteoporosis and a high incidence of fragility fractures have emerged as a complication of organ transplantation. Many factors contribute to the pathogenesis of osteoporosis following organ transplantation. In addition, most patients have some form of bone disease prior to transplantation, which is usually related to adverse effects of end-stage organ failure on the skeleton. This chapter reviews the mechanisms of bone loss that occur both in the early and late post-transplant periods, as well as the features specific to bone loss after kidney, lung, liver, cardiac and bone marrow transplantation. Prevention and treatment for osteoporosis should be instituted prior and in the early and late phase after transplantation, and will also be addressed in this article.


Nas últimas décadas houve um grande aumento no número de transplantes realizados no Brasil e no mundo, o que proporcionou uma melhora na sobrevida e qualidade de vida dos pacientes transplantados. A osteoporose e o aumento da prevalência de fraturas por fragilidade óssea têm se mostrado como uma complicação do transplante. Muitos fatores contribuem para a patogênese da osteoporose relacionada ao transplante. Além disso, a maioria dos pacientes apresenta doença óssea antes do transplante, a qual é secundária à doença grave de base. Este artigo revisa os mecanismos da perda óssea que ocorre tanto na fase precoce quanto na fase tardia após o transplante, como também os fatores específicos envolvidos na perda óssea relacionados ao transplante renal, pulmonar, cardíaco, hepático e de medula óssea. A prevenção e o tratamento da osteoporose em todas as fases do transplante também são abordados neste artigo.


Subject(s)
Humans , Osteoporosis/etiology , Transplantation/adverse effects , Bone Density , Bone Marrow Transplantation/adverse effects , Bone and Bones/drug effects , Heart Transplantation/adverse effects , Immunosuppressive Agents/adverse effects , Kidney Transplantation/adverse effects , Liver Transplantation/adverse effects , Lung Transplantation/adverse effects , Osteoporosis/prevention & control
11.
Rev. invest. clín ; 58(1): 78-79, ene.-feb. 2006. ilus
Article in Spanish | LILACS | ID: lil-632329

ABSTRACT

Renal graft rupture (RGR) is a life-threatening complication of kidney transplantation (KT), frequently associated with rejection and acute tubular necrosis. RGR repair with the use of suture, and corsetage with various materials (including synthetic glue, polyglactin absorbable hemostatic mesh, and lyophilized human dura), is indicated in non-severe cases. However, the employment of non-absorbable synthetic mesh had not been previously reported. Here, a case of a KT from cadaveric donor with RGR associated with acute rejection is reported. The graft was salvaged with the employment of a non-absorbable polypropylene mesh. Six months after KT, the patient remains asymptomatic with normal renal function. To the best of our knowledge, this is the first report of the use of a non-absorbable polypropylene mesh to repair a RGR. In a setting in which economical restrictions are important, the use of non-absorbable synthetic mesh may represent a good option of treatment.


La ruptura del injerto renal (RIR) es una complicación del trasplante renal (TR) que amenaza la vida, y frecuentemente está asociada a rechazo y necrosis tubular aguda. La reparación de la RIR con el uso de sutura y ferulización con varios materiales (incluyendo pegamento sintético, mallas hemostáticas absorbibles de poliglactina y duramadre liofilizada humana) está indicada en los casos no graves. Sin embargo, el empleo de mallas no absorbibles no había sido informado previamente. Aquí se informa el caso de un TR proveniente de donador cadavérico con RIR asociada a rechazo agudo. El injerto fue rescatado con el empleo de una malla no absorbible de polipropileno. Seis meses después del TR el paciente se encuentra asintomático con función renal normal. Hasta donde tenemos conocimiento, éste es el primer informe del uso de una malla no absorbible de polipropileno para reparar una RIR. En un medio con importantes restricciones económicas, el uso de mallas sintéticas no absorbibles puede representar una buena opción de tratamiento.


Subject(s)
Adult , Humans , Male , Kidney Transplantation , Kidney Diseases/surgery , Postoperative Complications/surgery , Surgical Mesh , Transplantation/adverse effects , Antilymphocyte Serum/therapeutic use , Gelatin Sponge, Absorbable , Graft Rejection/drug therapy , Graft Rejection/prevention & control , Hematoma/etiology , Immunosuppressive Agents/therapeutic use , Kidney Failure, Chronic/surgery , Methylprednisolone/therapeutic use , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use , Postoperative Hemorrhage/etiology , Prednisone/therapeutic use , Rupture, Spontaneous/surgery , T-Lymphocytes , Tacrolimus/therapeutic use , Transplantation/pathology
12.
Medical Journal of Islamic World Academy of Sciences. 2006; 15 (1-4): 27-30
in English | IMEMR | ID: emr-79075

ABSTRACT

The post-transplant lymphoproliferative disorder [PTLD] is defined in large part by their occurrence following organ transplantation and by their histopathological appearance. The vast majority is associated with Epstein -Barr virus [EBV] infection. Their recognition is important because underdiagnosis as a not otherwise specified reactive process may lead to continued immunosuppression and progression of disease and overdiagnosis as a conventional lymphoma may lead to inappropriate and potentially fatal chemotherapy. In this article pathogenesis, clinical cause, and therapy of PTLD have been presented and the role of EBV described


Subject(s)
Humans , Transplantation/adverse effects , Lymphoproliferative Disorders/etiology , Herpesvirus 1, Human
13.
Journal of Dentistry-Shiraz University of Medical Sciences. 2005; 6 (1, 2): 18-25
in Persian | IMEMR | ID: emr-71847

ABSTRACT

Nowadays transplantation is widely used to manage end organ failure, the way that saves patient's lives and increases their survival rate. But it has some complications such as posttransplant malignancies; one of them is posttransplant lymphoproliferative disorder [PTLD]. PTLD is more prevalent in children than in adults and it occurs from months to years after transplantation with the peak of 3-7 months. The incidence of PTLD after heart-lung transplantation is the most [9.4%] and after kidney transplantation is the least [1%]. The common sites of PTLD involvement include abdominal region [32%], bone marrow [25%] and other sites including head and neck [43%]. PTLD is related with immunosuppression caused by administration of immunosuppressive agents and is mostly accompanied by the proliferation of Epstein-Barr virus. Clinical presentation of PTLD varies from a self limiting mononucleosis to a generalized lymphoid infiltration or even a lymphoma. Management of PTLD includes reduction of immunosuppression, using anti CD20 antibody, antiviral drugs, chemothrapy and radiotherapy which are not so efficient. It's prognosis is poor and has 54% mortality rate. Clinical features of PTLD in head and neck region are cervical lymphadenopathy, generalized gingival hyperplasia with erythema, swelling, cyanotic foci and chronic mucosal ulcers; so this neccessitizes referring of a patient with such signs and symptoms or other suspicious conditions in the head and neck to a dentist for early diagnosis and biopsy. This article reviews PTLD with emphasis on oral manifestations and head and neck involvement


Subject(s)
Humans , Head and Neck Neoplasms , Head/pathology , Neck/pathology , Transplantation/adverse effects , Immunosuppression Therapy
14.
Bol. méd. Hosp. Infant. Méx ; 58(8): 537-564, ago. 2001. ilus, tab
Article in Spanish | LILACS | ID: lil-306734

ABSTRACT

Las infecciones en niños trasplantados requieren un estudio particular debido a su compromiso inmunológico. En la Ciudad de México se realizan trasplantes renales, de hígado y de médula ósea en la población infantil, cada vez en mayor número. Lo anterior obliga a conocer las infecciones que los afectan con la finalidad de realizar mejor prevención de éstas. El éxito del procedimiento quirúrgico también puede verse afectado por la presencia de infecciones graves. La vigilancia de las infecciones que afectan a esta población infantil debe realizarse con métodos que permitan identificar la presencia de infecciones activas para poder brindar un tratamiento anticipado y prevenir el desarrollo de enfermedad. En esta revisión se presentan los aspectos más relevantes en la prevención y el manejo de las infecciones bacterianas y fúngicas en niños trasplantados.


Subject(s)
Bacterial Infections , Mycoses , Immunocompromised Host , Transplantation/adverse effects , Heart-Lung Transplantation , Liver Transplantation , Kidney Transplantation
18.
RPG rev. pos-grad ; 4(2): 133-40, abr.-jun. 1997. ilus
Article in Portuguese | LILACS, BBO | ID: lil-197626

ABSTRACT

A hiperplasia gengival é a manifestaçäo bucal mais frequente associada à terapia com Ciclosporina (CsA). O objetivo do presente estudo foi avaliar os aspectos clínicos e histopatológicos da hiperplasia gengival induzida pela CsA em 10 pacientes pós-transplante de órgäos. Os resultados mostraram que a interaçäo de outras drogas com a CsA, assim como o grau de higiene bucal e a idade do paciente estäo relacionados com o desenvolvimento dessa lesäo


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Cyclosporine/adverse effects , Gingival Hyperplasia/diagnosis , Soft Tissue Injuries/complications , Drug Tolerance , Gingival Hyperplasia/physiopathology , Transplantation/adverse effects
19.
J. bras. med ; 71(5/6): 37-50, 52, 54, passim, nov.-dez. 1996. ilus, tab
Article in Portuguese | LILACS | ID: lil-186149

ABSTRACT

Os autores analisam as mais marcantes características das pneumonias nos enfermos imunossuprimidos nao-portadores de imunodeficiência adquirida. Discutem inicialmente os mecanismos de defesa pulmonar e os fatores predisponentes das infecçoes respiratórias, seguidos das manifestaçoes clínicas e dos achados radiológicos de tórax. As dificuldades de diagnóstico e o diagnóstico laboratorial sao apresentados de forma minuciosa, assim como os vários procedimentos adotados para a obtençao dos espécimes a serem empregados no reconhecimento da(s) etiologia(s). Sao finalmente apresentadas as estratégias utilizadas na abordagem clínica, no tratamento e nas medidas de profilaxia, seguidas de alguns exemplos de patologias de imunossuprimidos em nosso meio.


Subject(s)
Humans , Immunocompromised Host , Opportunistic Infections/complications , Pneumonia/immunology , Pneumonia/diagnosis , Pneumonia/therapy , Lung/immunology , Transplantation/adverse effects , Bone Marrow Transplantation/adverse effects
20.
Rev. argent. cir ; 58(6): 227-30, jun. 1990.
Article in Spanish | LILACS | ID: lil-95813

ABSTRACT

Se efectuaron 16 trasplantes unilaterales de pulmón izquierdo en perros. Como método de conservación se empleó el colapso pulmonar asociado a enfriamiento con solución fisiológica a 4 oC, inicialmente del "block" cardiopulmonar y ulteriormente del pulmón izquierdo a trasplantar. La anastomosis bronquial fue protegida envolviendo y fijando a su alrededor un pedículo de epiplón (9 perros) o un pedículo intercostal. El tiempo promedio de isquemia fue 125 minutos, sin hallarse relación entre su duración y la evolución postoperatoria. Se delimitaron 3 grupos de animales: 1) vinculados a una muerte anestésica y correlacionados histopatológicamente con edema pulmonar bilateral po fallas en la hidratación intraoperatoria; 2) aquellos que murieron al 4o día y presentaron trombosis en la satura venosa, falla técnica que se redujo al realizar sutura auricular con una guarda griega y 3) con sobrevida prolongada, cuyas necropsias presentaban infección , el control no fue comtemplado en este trabajo. La protección de la anastomosis bronquial con epiplón mostró mayor adaptación biológica respecto del pedículo intercostal.


Subject(s)
Dogs , Animals , Dogs/surgery , Lung/transplantation , Transplantation/adverse effects , Pulmonary Edema , Pulmonary Fibrosis , Thrombosis
SELECTION OF CITATIONS
SEARCH DETAIL